Sonoma Pharmaceuticals Inc (SNOA) Stock Price, Quote & News

Company Profile

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild t...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 800 759 9305

Website: sonomapharma.com

Address:

5445 Conestoga Court, Suite 150, Boulder, United States

topstockalerts Dec. 1 at 10:55 PM

After Hours Top Gainers PT2 $ARTL $CMND $IVF $LAB.X $SNOA

0 · Reply

SPACEDAD Dec. 1 at 9:20 PM

$SNOA on watch for possible short squeeze

0 · Reply

newbulloh2 Nov. 26 at 4:39 PM

$SNOA tank tank tank!!!! Below 2 in due time baby

0 · Reply

TradeHawk Nov. 21 at 5:54 PM

$SNOA Sonoma Pharmaceuticals and partner MicroSafe Care have received Australian Therapeutic Goods Administration approval for its Nanocyn Advanced Disinfectant & Sanitizer. https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=520725&agid=%28PrintDetailsPublic%29&actionid=1

0 · Reply

NVDAMillionaire Nov. 18 at 12:00 PM

$SNOA Brilliant piece that captures SNOA's situation perfectly. So if you want to update your understanding of SNOA or get to know SNOA better, this is essential reading. https://beyondspx.com/quote/SNOA/analysis/sonoma-pharmaceuticals-hocl-s-ascendance-in-dermatology-and-beyond-nasdaq-snoa

0 · Reply

Love_To_Learn Nov. 12 at 9:36 PM

$SNOA need u soon

0 · Reply

Don_Frye Nov. 7 at 7:35 PM

$SNOA im out of this pos with a loss . good luck

0 · Reply

_www_larval_com_ Nov. 4 at 3:01 PM

$SNOA has reverted 7% higher to -4% (~162Kv) moments ago, follow for more volatility.

0 · Reply

_www_larval_com_ Nov. 4 at 2:41 PM

$LPA -13%[-11%] $SNOA -12%[-11%] $MYGN -11%[-21%] $SY 7%[9%] $CJET -7%[-25%] most notable movement within the first minutes of trading.

0 · Reply

Swayz99 Nov. 4 at 2:03 PM

11/4 WL -> $VSEE (news, cheaper priced, ww for scalp plays) $SAGT (ww back over $2.50, needs vol first) $SCNX (another cheaper priced ww for scalps) $SNOA (backburner) Not seeing much at all this morning. The slowness continues with small caps. All it takes is one to get the momentum going again. Remaining patient this morning until I see something truly stand out. Trade the plan. Happy Huntin’!

0 · Reply

National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Nov 6, 2025, 4:01 PM EST - 4 weeks ago

Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf

Nov 4, 2025, 8:56 AM EST - 4 weeks ago

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results

Oct 14, 2025, 8:30 AM EDT - 7 weeks ago

Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals

Oct 7, 2025, 8:30 AM EDT - 2 months ago

Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA

Sep 25, 2025, 4:01 PM EDT - 2 months ago

Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Aug 26, 2025, 8:30 AM EDT - 3 months ago

National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced

Aug 13, 2025, 4:01 PM EDT - 4 months ago

Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains

Aug 7, 2025, 4:15 PM EDT - 4 months ago

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results

Jun 17, 2025, 4:10 PM EDT - 6 months ago

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results

Apr 22, 2025, 4:01 PM EDT - 8 months ago

Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain

Mar 10, 2025, 4:01 PM EDT - 9 months ago

Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

Feb 25, 2025, 4:01 PM EST - 10 months ago

Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando

Feb 5, 2025, 4:05 PM EST - 10 months ago

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results

Dec 5, 2024, 8:30 AM EST - 1 year ago

Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices

Nov 21, 2024, 4:06 PM EST - 1 year ago

Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States

Nov 11, 2024, 4:20 PM EST - 1 year ago

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel

Nov 7, 2024, 8:45 AM EST - 1 year ago

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf

Oct 22, 2024, 8:35 AM EDT - 1 year ago

Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada

Oct 21, 2024, 4:01 PM EDT - 1 year ago

Sonoma Pharmaceuticals to Present at Danisavage Financial Strategies, and LD Micro Main Event XVII Investor Conferences

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Sep 17, 2024, 8:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line

Aug 28, 2024, 6:10 AM EDT - 1 year ago

Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock

Aug 26, 2024, 8:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States

Aug 8, 2024, 4:10 PM EDT - 1 year ago

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine

Jun 17, 2024, 5:00 PM EDT - 1 year ago

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results

May 9, 2024, 7:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States

Apr 4, 2024, 7:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections

Mar 28, 2024, 4:01 PM EDT - 1 year ago

Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences

Mar 27, 2024, 7:30 AM EDT - 1 year ago

Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals

Feb 8, 2024, 4:10 PM EST - 1 year ago

Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results

Jan 23, 2024, 7:30 AM EST - 2 years ago

Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use

Jan 9, 2024, 9:15 AM EST - 2 years ago

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network

NBY

Nov 13, 2023, 4:10 PM EST - 2 years ago

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results

Nov 3, 2023, 7:30 AM EDT - 2 years ago

Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference

Oct 26, 2023, 9:10 AM EDT - 2 years ago

Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock

Aug 15, 2023, 7:30 AM EDT - 2 years ago

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board

Jun 22, 2023, 7:30 AM EDT - 2 years ago

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results

Jun 9, 2023, 5:05 PM EDT - 2 years ago

Sonoma Pharmaceuticals Shares Soar 44% After Introducing New Product

Jun 8, 2023, 4:01 PM EDT - 2 years ago

Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

Apr 11, 2023, 7:30 AM EDT - 2 years ago

Sonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot Care

Mar 28, 2023, 4:15 PM EDT - 2 years ago

Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in Philadelphia

Mar 2, 2023, 7:30 AM EST - 3 years ago

Sonoma Pharmaceuticals and MicroSafe Group Announce New EPA Claims and Green Seal Certification for Nanocyn(R) Hospital-Grade Disinfectant

topstockalerts Dec. 1 at 10:55 PM

After Hours Top Gainers PT2 $ARTL $CMND $IVF $LAB.X $SNOA

0 · Reply

SPACEDAD Dec. 1 at 9:20 PM

$SNOA on watch for possible short squeeze

0 · Reply

newbulloh2 Nov. 26 at 4:39 PM

$SNOA tank tank tank!!!! Below 2 in due time baby

0 · Reply

TradeHawk Nov. 21 at 5:54 PM

0 · Reply

NVDAMillionaire Nov. 18 at 12:00 PM

0 · Reply

Love_To_Learn Nov. 12 at 9:36 PM

$SNOA need u soon

0 · Reply

Don_Frye Nov. 7 at 7:35 PM

$SNOA im out of this pos with a loss . good luck

0 · Reply

_www_larval_com_ Nov. 4 at 3:01 PM

$SNOA has reverted 7% higher to -4% (~162Kv) moments ago, follow for more volatility.

0 · Reply

_www_larval_com_ Nov. 4 at 2:41 PM

$LPA -13%[-11%] $SNOA -12%[-11%] $MYGN -11%[-21%] $SY 7%[9%] $CJET -7%[-25%] most notable movement within the first minutes of trading.

0 · Reply

Swayz99 Nov. 4 at 2:03 PM

0 · Reply

Stock_Catcher Nov. 4 at 1:56 PM

$SNOA Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results

0 · Reply

pinupinu Nov. 3 at 9:24 AM

$ACET $IXHL $RVYL $SNOA $WGRX bang on RVYl to $2

0 · Reply

SofritoKid1 Nov. 2 at 6:54 PM

🔮 This week bangers 🔥 $WGRX - Monday Open $SNOA $ACET- Monday Open $RVYL $IXHL

1 · Reply

Don_Frye Oct. 24 at 5:57 PM

$SNOA hahaha somebody wants in

0 · Reply

Bigdubs Oct. 23 at 10:02 PM

$SNOA WTF mate... What did Bruce do to you Amy!?

0 · Reply

Benderama8 Oct. 23 at 9:50 PM

$SNOA Amy Trombly fired Bruce Thornton FOR CAUSE without pay, LOL. Put a fork in this company, they are done.

1 · Reply

SimpleLogic85 Oct. 22 at 1:07 PM

$SNOA this stupid shit not doi g nothing

0 · Reply

bobby1618 Oct. 18 at 2:01 AM

$SNOA looks like a really good investment I'm buying on Monday

0 · Reply

BenGang Oct. 16 at 10:32 PM

$SNOA

0 · Reply

Dickman777 Oct. 15 at 1:13 PM

$INV added here $SNOA gather what you can and thank yourself!!

0 · Reply

Jimmystocks6967 Oct. 14 at 6:22 PM

$SNOA how is this red on that news? Weird not even a few cents up looks like good news could be millions of $

1 · Reply

Bigdubs Oct. 14 at 3:45 PM

$SNOA Amy still can’t get the volume to fund her ATM on two PRs.

0 · Reply

Market Cap	5.39M
Revenue (ttm)	14.29M
Net Income (ttm)	-3.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-24.21%
Debt to Equity Ratio	0.00

Volume	31,900
Avg Vol	45,410
Day's Range	N/A - N/A
Shares Out	1.70M
Stochastic %K	91%
Beta	1.64
Analysts	Sell
Price Target	$14.80